Oral fluoropyrimidine treatment of colorectal cancer

Clinical colorectal cancer

Volumn 1, Issue 2, 2001, Pages 95-103

  Eng, Cathy ^a   Kindler, Hedy L ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EMITEFUR; FLUOROURACIL; OXALIPLATIN; OXONIC ACID; PLATINUM COMPLEX; PRODRUG; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

CLINICAL TRIAL; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PATIENT COMPLIANCE; PRODRUGS; PYRIDINES; TEGAFUR; TREATMENT OUTCOME;

EID: 0035428097     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2001.n.009     Document Type: Review

References (51)

1. C Heidelberger N Chaudhuari P Daneberg Fluorinated pyrimidines. a new class of tumor inhibiting compounds Nature 179 1957 633 666
2. Meta-analysis Group In Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 1998 301 308
3. JJ Lokich JD Ahlgren JJ Gullo A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study J Clin Oncol 7 1989 425 432
4. L Iyer MJ Ratain 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy Cancer Invest 17 1999 494 506
5. RB Diasio BE Harris Clinical pharmacology of 5-fluorouracil Clin Pharmacokinet 16 1989 215 237
6. GD Heggie JP Sommadossi DS Cross Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 1987 2203 2206
7. JL Grem LK Yee DJ Venzon Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells Cancer Chemother Pharmacol 40 1997 117 125
8. Z Lu R Zhang RB Diasio Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy Clin Pharmacol Ther 58 1995 512 522
9. FN Naguib MH el Kouni S Cha Enzymes of uracil catabolism in normal and neoplastic human tissues Cancer Res 45 1985 5405 5412
10. JL Grem 5-fluoropyrimidines BA Chabner DL Longo Cancer Chemotherapy and Biotherapy 1996 Lippincott-Raven Philadelphia, PA 146 211
11. WJ Hrushesky R Von Roemeling EE Fraley Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma Semin Surg Oncol 4 1988 110 115
12. RB Diasio Z Lu Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy J Clin Oncol 12 1994 2239 2242
13. G Liu E Franssen MI Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
14. G Bonadonna P Valagussa Dose-response effect of adjuvant chemotherapy in breast cancer N Engl J Med 304 1981 10 15
15. AH Lebovits JJ Strain SJ Schleifer Patient noncompliance with self-administered chemotherapy Cancer 65 1990 17 22
16. MD DeMario MJ Ratain Oral chemotherapy: rationale and future directions J Clin Oncol 16 1998 2557 2567
17. AM Levine JL Richardson G Marks Compliance with oral drug therapy in patients with hematologic malignancy J Clin Oncol 5 1987 1469 1476
18. S Sharma LB Saltz Oral chemotherapeutic agents for colorectal cancer Oncologist 5 2000 99 107
19. 1999 Drug Topics Red Book 1999 Medical Economics Company Montevale, NJ
20. A Murad CA de Andrade C Delfino A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America Oncology (Huntingt) 11 1997 128 135
21. Y Takebayashi S Akiyama S Akiba Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma J Natl Cancer Inst 88 1996 1110 1117
22. T Ishikawa F Sekiguchi Y Fukase Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts Cancer Res 58 1998 685 690
23. J Schuller J Cassidy E Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
24. EB Lamont RL Schilsky The oral fluoropyrimidines in cancer chemotherapy Clin Cancer Res 5 1999 2289 2296
25. DR Budman NJ Meropol B Reigner Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine J Clin Oncol 16 1998 1795 1802
26. M Mackean A Planting C Twelves Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J Clin Oncol 16 1998 2977 2985
27. E van Cutsem M Findlay B Osterwalder Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study J Clin Oncol 18 2000 1337 1345
28. P Hoff J Abbruzzese D Medgyesy A phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5-FU therapy Proc Am Soc Clin Oncol 19 2000 256a (Abstract #993).
29. C Twelves P Harper E van Cutsem A phase III trial (S014796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 263a (Abstract #1010).
30. PM Hoff R Ansari G Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
31. JL Au W Sadee The pharmacology of ftorafur (R, S-1-(tetrahydro- 2-furanyl)-5-fluorouracil Recent Results Cancer Res 76 1981 100 114
32. RA Brito D Medgyesy TH Zukowski Fluoropyrimidines: a critical evaluation Oncology 57 suppl 1 1999 2 8
33. T Taguchi Experience with UFT in Japan Oncology (Huntingt) 11 1997 30 34
34. R Pazdur Y Lassere E Diaz-Canton Phase I trials of uraciltegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities Anticancer Drugs 7 1996 728 733
35. R Pazdur W Covington Y Brown Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (5-FU) Proc Am Soc Clin Oncol 15 1996 474 (Abstract #1498).
36. R Pazdur J-Y Douillard J Skillings Multicenter phase III study of 5-fluorouracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 263a (Abstract #1009).
37. T Taguchi Y Inuyama R Kanamaru Phase I study of S-1. S-1 study group Gan To Kagaku Ryoho 24 1997 2253 2264
38. CJ van Groeningen GJ Peters JH Schornagel Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors J Clin Oncol 18 2000 2772 2779
39. P Hoff C Wenske D Medgyesy Phase I and pharmacokinetic (PK) study of the novel oral fluoropyrimidine, S-1 Proc Am Soc Clin Oncol 18 1999 173a (Abstract #665).
40. M Sano T Saeki S Takashima Late phase II study of S-1 in patients with advanced and/or recurrent breast cancer Proc Am Soc Clin Oncol 19 2000 105a (Abstract #404).
41. M Fujii J Kanzaki B Satake Early phase II study of S-1 in patients with advanced head and neck cancer Proc Am Soc Clin Oncol 15 1996 316 (Abstract #894).
42. H Baba A Ohtsu Y Sakata Late phase III study of S-1 in patients with advanced colorectal cancer in Japan Proc Am Soc Clin Oncol 17 1998 277a (Abstract #1065).
43. PM Hoff M Royce D Medgyesy Oral fluoropyrimidines Semin Oncol 26 1999 640 646
44. S Fujii M Fukushima Y Shimamoto Antitumor activity of BOF-A2, a new 5-fluorouracil derivative Jpn J Cancer Res 80 1989 173 181
45. C Matei P Hoff R Brito Phase I trial of oral BOF-A2 plus leucovorin (LV) in advanced colorectal cancer (CRC): antitumor activity in fluorouracil-resistant patients Proc Am Soc Clin Oncol 17 1998 230a (Abstract #882).
46. L Saltz P Locker N Pirotta Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC) Proc Am Soc Clin Oncol 18 1999 233a (Abstract #898).
47. RF Morton RM Goldberg DJ Sargent Oxaliplatin (OXAL) or CPT-11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC): an NCCTG/CALGB study Proc Am Soc Clin Oncol 20 2001 125a (Abstract #495).
48. N Schleucher M Tewes W Achterrath Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer Proc Am Soc Clin Oncol 20 2001 141a (Abstract #561).
49. P Escudero A Vicente A Herrero Phase I-II trial of irinotecan (CPT-11) over a short IV weekly infusion combined with a fixed dose of UFT in second line advanced colorectal carcinoma (ACRC) Proc Am Soc Clin Oncol 19 2000 257a (Abstract #1136).
50. JY Douillard JF Seitz A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC) Proc Am Soc Clin Oncol 20 2001 144a (Abstract #572).
51. MM Borner S Mueller A Roth Phase II study of capecitabine (CAP) + oxaliplatin (OXA) in first line and second line treatment of advanced or metastatic colorectal cancer (ACC) Proc Am Soc Clin Oncol 20 2001 137a (Abstract #546).